Immunological and Microbiological perspectives on Irritable Bowel Syndrome. by Bennet, Sean
Göteborg, 2017 
SAHLGRENSKA AKADEMIN 
Immunological and Microbiological perspectives 
on Irritable Bowel Syndrome 
Akademisk avhandling 
Som för avläggande av medicine doktorsexamen vid Sahlgrenska akademin, 
Göteborgs universitet kommer att offentligen försvaras i Karl Isaksson, 
Medicinaregatan 16, Göteborg, fredag den 15 december, klockan 13:00 
av Sean Bennet 
Fakultetsopponent: 
Professor Stephen Vanner  
Depts. of Medicine, and Biomedical and Molecular Sciences, 
Queen's University, Canada 
Avhandlingen baseras på följande delarbeten 
I. Multivariate modelling of faecal bacterial profiles of patients with IBS 
predicts responsiveness to a diet low in FODMAPs 
Bennet SMP, Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, 
Öhman L and Simrén M. Gut 2017 Apr 17. [Epub ahead of print].  
II. Global cytokine profiles and association with clinical characteristics in 
patients with irritable bowel syndrome 
Bennet SMP, Polster A, Törnblom H, Isaksson S, Capronnier S, Tessier A, Le 
Nevé B, Simrén M and Öhman L. Am J Gastroenterol 2016;111:1165-76. 
III. Systemic cytokines are elevated in a subset of patients with irritable bowel 
syndrome (IBS) but largely unrelated to symptom characteristics 
Bennet SMP,  Palsson O, Whitehead WE, Barrow DA, Törnblom H, Öhman L, 
Simrén M and van Tilburg MAL. Submitted 
IV. Altered intestinal antibacterial gene expression response profile in irritable 
bowel syndrome is linked to bacterial composition and immune activation 
Bennet SMP#, Sundin J#, Magnusson MK, Strid H, Tap J, Derrien M, Le Nevé 
B, Doré J, Törnblom H, Simrén M* and Öhman L*. Submitted
INSTITUTIONEN FÖR MEDICIN 
Göteborg, 2017 
ISBN: 978-91-629-0376-3 (PRINT)  
ISBN: 978-91-629-0377-0 (e-pub) 
 
 
Immunological and Microbiological perspectives 
on Irritable Bowel Syndrome 
Sean Bennet 
invärtesmedicin och klinisk nutrition, Institutionen för medicine, Sahlgrenska 
akademin, Göteborgs universitet, Sverige, 2017. 
Abstract 
Irritable bowel syndrome affects ~11% of the population in the Western world and is 
characterised by altered bowel habits and abdominal pain. The range of additional 
symptoms between subjects makes the group of IBS patients heterogeneous. Increased 
immune activity, altered gut microbiota and diet are implicated in symptom generation 
though the mechanisms are poorly understood. Moreover, gut microbiota and immune 
activity interplay in relation to symptoms requires elucidation and while dietary 
intervention is effective in some patients its impact on gut microbiota is unclear. Most 
likely, all patients do not share the same symptom generating mechanisms, and thus 
better means to stratify patients for both research and treatment is required.This thesis 
aimed to demonstrate how gut microbiota, the immune system and their crosstalk 
result in symptom generation in IBS patients. Furthermore, we aimed to demonstrate 
how dietary intervention affects microbiota of the gut and if patient responsiveness to 
intervention therapy could be predicted by gut microbiota profiles.This thesis 
demonstrates that a diet low in poorly absorbed carbohydrates (FODMAP) changes 
the gut microbiota composition and reduces beneficial bacteria in IBS patients. 
Moreover, the composition of gut microbiota can be used to discriminate patients 
whose IBS symptoms improved or not after a low FODMAP diet. Additionally, serum 
or mucosal cytokines cannot be used alone to diagnose IBS. However, a subset of 
immuno-active patients had comparatively raised serum levels of pro-inflammatory 
cytokines to healthy subjects and immuno-normal IBS patients, although no major 
associations between cytokines and symptoms were found. Further, IBS patients had 
an altered mucosal expression of genes associated with an innate antimicrobial 
response compared to healthy subjects. The antibacterial gene expression response 
profiles as well as faecal and mucosal bacterial profiles were different between 
immuno-active and immuno-normal IBS patients, but were not associated to 
symptoms. In conclusion, a subset of IBS patients has altered immune activity, 
deemed by cytokine and innate antimicrobial response profiles, which do not seem to 
be associated with any specific symptom profile. Further, faecal microbial profiles 
may be used to identify responders to low FODMAP diet therapy but negative impact 
of the diet on beneficial bacteria requires further investigation. Thus, this thesis has 
identified novel subgroups of IBS patients based on underlying mechanisms which 
may guide development of innovative therapy options. 
Keywords: IBS, Microbiota, Immune system, FODMAPs 
